There is likely some truth with the mention of Incyte’s adult GVHD drug by @Phaedrus in his latest reply to one of your previous posts, LeftYahoo, that there was a competitive consideration in how SI perhaps decided on using children’s aGVHD as a lead indication, given that the giant Novartis owns Incyte. So it might have been a miscalculation, and being too timid in deciding that as a small biotech, that was the best way forward ie. in avoiding head-on competition by going down the children’s indication. I do, however, agree that what it might have thought of as a strategic move has cost the company hugely.
@Led - what are your thoughts as to how to incorporate these considerations into the next steps?
- Forums
- ASX - By Stock
- MSB
- CEO Itescu needs to go
CEO Itescu needs to go, page-708
-
-
- There are more pages in this discussion • 200 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.11 |
Change
0.005(0.45%) |
Mkt cap ! $1.250B |
Open | High | Low | Value | Volume |
$1.08 | $1.12 | $1.08 | $1.558M | 1.431M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
22 | 76058 | $1.11 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.11 | 27976 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
30 | 33213 | 1.110 |
14 | 80724 | 1.105 |
14 | 117735 | 1.100 |
14 | 315747 | 1.095 |
10 | 68460 | 1.090 |
Price($) | Vol. | No. |
---|---|---|
1.115 | 106564 | 18 |
1.120 | 110006 | 10 |
1.125 | 126541 | 14 |
1.130 | 106891 | 5 |
1.135 | 17418 | 1 |
Last trade - 12.30pm 19/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |